Caraco launches colon, rectal cancer generic

DETROIT Caraco Pharmaceutical Labs has launched a generic version of a drug for treating colon and rectal cancer, the generic drug maker announced Thursday.

Caraco, the U.S. subsidiary of India-based Sun Pharmaceutical Industries, launched the injectable oxaliplatin in the 50-mg and 100-mg strengths.

The drug is a generic version of Sanofi-Aventis’ Eloxatin. According to Caraco, injectable oxaliplatin has annual sales of around $1.3 billion annually.